28 results match your criteria: "National Allergy Asthma Bronchitis Institute[Affiliation]"
Pulm Ther
December 2024
Medical Affairs & Clinical Research, Sun Pharma Laboratories Limited, Mumbai, India.
A severe and progressive interstitial lung disease (ILD) known as idiopathic pulmonary fibrosis (IPF) has an unknown etiology with poorly defined mechanisms of development. Among the currently prescribed pharmacological interventions for IPF, nintedanib demonstrates the ability to decelerate the deterioration of lung function and yield positive clinical outcomes. Multiple randomized placebo-controlled trials have confirmed the efficacy and acceptable safety profile of nintedanib.
View Article and Find Full Text PDFLung India
January 2023
84, Sawarkar Nagar, P O Vivekanand Nagar, Nagpur, India.
J Assoc Physicians India
June 2023
Consultant Chest Physician, Department of Pulmonary Medicine, Chest Research and Training (CREST), Pune, Maharashtra.
Background: The use of nebulizers is an important and useful method for delivering drugs to the lungs in patients with various airway and lung parenchymal disorders. They are primarily used in patients with acute symptoms and in a selected group of patients for maintenance treatment. Its use has increased, especially during the coronavirus disease 2019 (COVID-19) pandemic.
View Article and Find Full Text PDFIndian J Tuberc
November 2022
Interventional Pulmonology, Yashoda Hospitals, Hyderabad, Telangana, India.
Inhalational therapy, today, happens to be the mainstay of treatment in obstructive airway diseases (OADs), such as asthma, chronic obstructive pulmonary disease (COPD), and is also in the present, used in a variety of other pulmonary and even non-pulmonary disorders. Hand-held inhalation devices may often be difficult to use, particularly for children, elderly, debilitated or distressed patients. Nebulization therapy emerges as a good option in these cases besides being useful in the home care, emergency room and critical care settings.
View Article and Find Full Text PDFERJ Open Res
April 2022
Dept of Respiratory Medicine, Asthma Bhawan, Jaipur, India.
Objective: The objective of this subanalysis of data from centres across urban areas in India of the Global Asthma Network (GAN) was to study 1) the prevalence of symptoms of asthma in children and adults, 2) the change in prevalence of asthma and its trigger factors since the International Study of Asthma and Allergies in Childhood (ISAAC), and 3) current asthma treatment practice.
Methods: In this cross-sectional, multicentre, school-based and self-administered questionnaire, responses from children aged 6-7 years and 13-14 years, and their respective parents, were analysed.
Results: The GAN Phase I study included 20 084 children in the 6-7-year age group, 25 887 children in the 13-14-year age group and 81 296 parents.
J Allergy Clin Immunol Glob
May 2022
Chest Research Foundation, Pune, India.
Background: The Global Asthma Network phase I study in India aimed to study the prevalence, time trends, and associated risk factors of allergic rhinitis and eczema among 6-7-year-old, and 13-14-year-old school children and their parents. The objective of the study was to understand the current prevalence and associated risk factors of Allergic Rhinitis and Eczema in India among 6-7-year-olds, 13-14-year-olds and in their parents/guardians for newer directions to health care providers, policy makers and academicians.
Methods: Cross-sectional, multicenter study using self- and parent-administered questionnaire among randomly selected school children aged 6 to 7 years from 8 centers and 13 to 14 years from 9 centers and their respective parents/guardians across India.
Lung India
March 2021
Department of Pulmonary Medicine, PGIMER, Chandigarh, India.
Lung India
January 2021
Department of Medicine, Center for Interstitial Lung Diseases, University of Washington, Seattle, WA, USA.
Background: Predictors of survival for interstitial lung disease (ILD) in the Indian population have not been studied. The primary objective of the study was to assess the Modified-Gender Age and Physiology (M-GAP) score to predict survival in patients with ILD seen in clinical practice. We also analyzed the role of demographic and radiological characteristics in predicting the survival of patients with ILD.
View Article and Find Full Text PDFLung India
August 2020
Department of Internal and Pulmonary Medicine, Sher-i-Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India.
Similar to the global scenario, pneumococcal diseases are a significant health concern in India. Pneumococcal diseases occur frequently among adults and are largely preventable through vaccines. Globally, several guidelines and recommendations are available for pneumococcal vaccination in adults.
View Article and Find Full Text PDFLung India
August 2020
Department of Internal and Pulmonary Medicine, Sher-i-Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India.
Influenza, a common cause of acute respiratory infections, is an important health problem worldwide, including in India. Influenza is associated with several complications; people with comorbidities and the elderly are at a higher risk for such complications. Moreover, the influenza virus constantly changes genetically, thereby worsening therapeutic outcomes.
View Article and Find Full Text PDFLung India
January 2020
Department of Medicine, University of Washington, Seattle, USA.
Pulm Pharmacol Ther
February 2020
Medical Dept, Cipla Ltd, Mumbai, India. Electronic address:
The combination of inhaled corticosteroids (ICS) and long-acting beta-agonists (LABAs) is widely used for the management of asthma. This prospective, open-label, non-comparative, observational, 24-week multicentre study is the first real-world study from India to compare the efficacy and safety of fixed-dose combination of fluticasone/formoterol (Maxiflo® 100/6 mcg or 250/6 mcg) capsules via the Revolizer® device in patients with persistent asthma. The primary efficacy analyses included mean change in Asthma Control Test (ACT™) at 4, 8, 16 and 24 weeks.
View Article and Find Full Text PDFLung India
January 2019
Department of Medicine, Center for Interstitial Lung Diseases, University of Washington, Seattle, WA 98195, USA.
Context: Multiple environmental factors are associated with development of hypersensitivity pneumonitis (HP), and diagnostic algorithms for the diagnosis of HP have been proposed in recent perspectives.
Aims: We analyzed the data of patients with HP from interstitial lung disease (ILD)-India registry. The analysis was performed to (1) find the prevalence of HP, (2) reclassify HP as per a recently proposed classification criterion to assess the level of diagnostic certainty, and (3) identify the causative agents for HP.
Lung India
January 2019
Respiratory, Critical Care & Sleep Medicine, Getwell Hospital, Nagpur, Maharashtra, India.
Globally, pneumococcal diseases are a significant public health concern. They are preventable and frequently occur among older adults. Major risk factors for the disease are extremes of age, alcohol intake, smoking, air pollution, and comorbid conditions (diabetes, chronic obstructive pulmonary disease, chronic kidney disease, liver disease, and heart disease).
View Article and Find Full Text PDFJ Assoc Physicians India
January 2019
Consultant Chest Physician, Rakshit Hospital, Chennai, Tamil Nadu.
Int Arch Allergy Immunol
September 2018
Medical Affairs Asia-Pacific Region, Merck & Co., Inc., Kenliworth, New Jersey, USA.
Background: Allergic rhinitis (AR), asthma, chronic obstructive pulmonary disease (COPD), and rhinosinusitis are common and little studied in the Asia-Pacific region.
Objectives: We sought to investigate real-world practice patterns for these respiratory diseases in India, Korea, Malaysia, Singapore, Taiwan, and Thailand.
Methods: This cross-sectional observational study enrolled adults (age ≥18 years) presenting to general practitioners (GP) or specialists for physician-diagnosed AR, asthma, COPD, or rhinosinusitis.
J Assoc Physicians India
May 2017
PSG Hospital, Coimbatore, Tamil Nadu; 6Fortis Hospitals, Kolkata, West Bengal.
Recent years have seen an increase in the use of nebulizers for delivering maintenance therapy in obstructive airway diseases (OADs) such as asthma and chronic obstructive pulmonary disease (COPD). The probable factors associated with this increase at home are: convenience of drug delivery, technological advances making the nebulizer equipment more efficient and portable, increase in the prevalence of OADs and the ageing population which may impact the optimal use of handheld inhalers such as pressurized metered dose inhalers (pMDIs) and dry powder inhalers (DPIs). Although there is increase in the use of maintenance therapy with nebulization, there has been no such increase in the evidence base available for the appropriate use of nebulizers.
View Article and Find Full Text PDFLung India
January 2016
Department of Otolaryngology, National University of, Singapore.
Background: Chronic respiratory diseases such as asthma, allergic rhinitis (AR), chronic obstructive pulmonary disease (COPD), and rhinosinusitis are becoming increasingly prevalent in the Asia-Pacific region. The Asia-Pacific Burden of Respiratory Diseases study examined the disease and economic burden of AR, asthma, COPD, and rhinosinusitis across the Asia-Pacific and more specifically India.
Objectives: To estimate the proportion of adults receiving care for asthma, AR, COPD, and rhinosinusitis and assess the economic burden, both direct and indirect of these chronic respiratory disease.
Value Health Reg Issues
May 2016
Division of Asthma, Allergy and Clinical Immunology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea. Electronic address:
Objectives: Asia-Pacific Burden of Respiratory Diseases is a cross-sectional, observational study examining the burden of disease in adults with respiratory diseases across six countries. The aim of this study was to describe health care resource use (HCRU), work impairment, cost burden, and health-related quality of life (HRQOL) associated with respiratory disease in the Asia-Pacific.
Methods: Consecutive participants aged 18 years or older with a primary diagnosis of asthma, allergic rhinitis, chronic obstructive pulmonary disease, or rhinosinusitis were enrolled.
Am J Respir Crit Care Med
March 2017
2 Department of Medicine.
Rationale: Interstitial lung disease (ILD) is a heterogeneous group of acute and chronic inflammatory and fibrotic lung diseases. Existing ILD registries have had variable findings. Little is known about the clinical profile of ILDs in India.
View Article and Find Full Text PDFBackground: Despite a better understanding of the pathophysiology of asthma, presence of reliable diagnostic tools, availability of a wide array of effective and affordable inhaled drugs and simplified national and international asthma management guidelines, asthma remains poorly managed in India.
Objective: The Asia-Pacific Asthma Insight and Management (AP-AIM) study was aimed at understanding the characteristics of asthma, current management, level of asthma control and its impact on quality of life across Australia, China, Hong Kong, India, Malaysia, Singapore, South Korea, Taiwan and Thailand. This paper describes the results of asthma management issues in India in detail and provides a unique insight into asthma in India.
Allergy Asthma Immunol Res
November 2016
Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Purpose: The Asia-Pacific Burden of Respiratory Diseases (APBORD) study is a cross-sectional, observational one which has used a standard protocol to examine the disease and economic burden of allergic rhinitis (AR), asthma, chronic obstructive pulmonary disorder (COPD), and rhinosinusitis across the Asia-Pacific region. Here, we report on symptoms, healthcare resource use, work impairment, and associated costs in Korea.
Methods: Consecutive participants aged ≥18 years with a primary diagnosis of asthma, AR, COPD, or rhinosinusitis were enrolled.
Medicine (Baltimore)
July 2016
Department of Otorhinolaryngology, Faculty of Medicine, Khon Kaen University, Thailand Seoul National University Hospital, Korea National Allergy Asthma Bronchitis Institute, India Institute of Respiratory Medicine, Malaysia Chang Gung Memorial Hospital, Taiwan Chiangmai University Faculty of Medicine Siriraj Hospital, Mahidol University Chulalongkorn University, Thailand Merck & Co., Inc., NJ, USA Optum, Sydney, NSW, Australia National University of Singapore, Singapore.
Asia-Pacific Burden of Respiratory Diseases (APBORD) was a cross-sectional, observational study examining the burden of respiratory disease in adults across 6 Asia-Pacific countries.This article reports symptoms, healthcare resource utilization (HCRU), work impairment and cost burden associated with allergic rhinitis (AR), asthma, chronic obstructive pulmonary disease (COPD), and rhinosinusitis in Thailand.Consecutive participants aged ≥18 years with a primary diagnosis of AR, asthma, COPD, or rhinosinusitis were enrolled at 4 hospitals in Thailand during October 2012 and October 2013.
View Article and Find Full Text PDFMedicine (Baltimore)
July 2016
Department of Thoracic Medicine, Chang Gung Memorial Hospital, Taipei, Taiwan Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea National Allergy Asthma Bronchitis Institute, Kolkota, West Bengal, India Institute of Respiratory Medicine, Kuala Lumpur, Malaysia Department of Otorhinolaryngology, Faculty of Medicine, Khon Kaen University, Thailand Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc. NJ Life Sciences, Optum, Sydney, NSW, Australia Department of Otolaryngology, National University of Singapore, Singapore.
Chronic respiratory diseases such as asthma, allergic rhinitis (AR), chronic obstructive pulmonary disease (COPD), and rhinosinusitis are becoming increasingly prevalent in the Asia-Pacific region. The Asia-Pacific Burden of Respiratory Diseases (APBORD) study was a cross-sectional, observational study which examined the disease and economic burden of AR, asthma, COPD, and rhinosinusitis across Asia-Pacific using 1 standard protocol. Here we report symptoms, healthcare resource use (HCRU), work impairment, and associated cost in Taiwan.
View Article and Find Full Text PDFLung India
July 2015
Writing Committee of the Indian Initiative on Obstructive Sleep Apnoea Guidelines Working Group ; Indian Council of Medical Research, New Delhi, India.
Obstructive sleep apnea (OSA) and obstructive sleep apnea syndrome (OSAS) are subsets of sleep-disordered breathing. Awareness about OSA and its consequences among the general public as well as the majority of primary care physicians across India is poor. This necessitated the development of the Indian initiative on obstructive sleep apnea (INOSA) guidelines under the auspices of Department of Health Research, Ministry of Health and Family Welfare, Government of India.
View Article and Find Full Text PDF